![]() |
Name |
3,3,8-Trimethyldecane
|
Molecular Formula | C13H28 | |
IUPAC Name* |
3,3,8-trimethyldecane
|
|
SMILES |
CCC(C)CCCCC(C)(C)CC
|
|
InChI |
InChI=1S/C13H28/c1-6-12(3)10-8-9-11-13(4,5)7-2/h12H,6-11H2,1-5H3
|
|
InChIKey |
IWDBBRKPCLWIKU-UHFFFAOYSA-N
|
|
Synonyms |
3,3,8-TRIMETHYLDECANE; 62338-16-3; Decane, 3,3,8-trimethyl-; 3,3,8-Trimethyldecane #; DTXSID10977895
|
|
CAS | 62338-16-3 | |
PubChem CID | 44006 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 184.36 | ALogp: | 6.5 |
HBD: | 0 | HBA: | 0 |
Rotatable Bonds: | 7 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 0.0 | Aromatic Rings: | 0 |
Heavy Atoms: | 13 | QED Weighted: | 0.467 |
Caco-2 Permeability: | -4.438 | MDCK Permeability: | 0.00000834 |
Pgp-inhibitor: | 0.09 | Pgp-substrate: | 0 |
Human Intestinal Absorption (HIA): | 0.005 | 20% Bioavailability (F20%): | 0.819 |
30% Bioavailability (F30%): | 0.902 |
Blood-Brain-Barrier Penetration (BBB): | 0.517 | Plasma Protein Binding (PPB): | 97.89% |
Volume Distribution (VD): | 2.824 | Fu: | 2.46% |
CYP1A2-inhibitor: | 0.467 | CYP1A2-substrate: | 0.836 |
CYP2C19-inhibitor: | 0.571 | CYP2C19-substrate: | 0.91 |
CYP2C9-inhibitor: | 0.375 | CYP2C9-substrate: | 0.943 |
CYP2D6-inhibitor: | 0.079 | CYP2D6-substrate: | 0.318 |
CYP3A4-inhibitor: | 0.308 | CYP3A4-substrate: | 0.172 |
Clearance (CL): | 5.616 | Half-life (T1/2): | 0.111 |
hERG Blockers: | 0.065 | Human Hepatotoxicity (H-HT): | 0.017 |
Drug-inuced Liver Injury (DILI): | 0.042 | AMES Toxicity: | 0.006 |
Rat Oral Acute Toxicity: | 0.047 | Maximum Recommended Daily Dose: | 0.025 |
Skin Sensitization: | 0.656 | Carcinogencity: | 0.055 |
Eye Corrosion: | 0.992 | Eye Irritation: | 0.957 |
Respiratory Toxicity: | 0.527 |